Cipla Limited — Ondansetron Exporter Profile
Indian Pharmaceutical Exporter · #10 for Ondansetron · $3.0M export value · DGFT Verified
Cipla Limited is the #10 Indian exporter of Ondansetron with $3.0M in export value and 204 verified shipments. Cipla Limited holds a 2.4% market share in Ondansetron exports across 7 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Ondansetron Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Ondansetron?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SOUTH AFRICA | $744.0K | 27 | 28.5% |
| SRI LANKA | $472.9K | 19 | 18.1% |
| COLOMBIA | $467.7K | 35 | 17.9% |
| YEMEN | $262.5K | 8 | 10.0% |
| SWEDEN | $254.6K | 48 | 9.7% |
| UNITED KINGDOM | $207.1K | 60 | 7.9% |
| YEMEN, DEMOCRATIC | $190.2K | 5 | 7.3% |
| NEW ZEALAND | $15.0K | 2 | 0.6% |
Cipla Limited exports Ondansetron to 8 countries. The largest destination is SOUTH AFRICA accounting for 28.5% of Cipla Limited's Ondansetron shipments, followed by SRI LANKA (18.1%) and COLOMBIA (17.9%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Ondansetron from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| BREATHEFREE LANKA PVT LTD | SRI LANKA | $372.9K | 17 |
| MEDPRO PHARMACEUTICA (PTY) LTD | SOUTH AFRICA | $366.5K | 15 |
| CIPLA COLOMBIA SAS Y/O DEPOSITO UPS | COLOMBIA | $323.3K | 26 |
| AL JABAL GROUP FOR TRADE INVESTMENT | YEMEN | $262.5K | 8 |
| ALLOGA UK LTD | UNITED KINGDOM | $196.5K | 57 |
| AL-JABAL GROUP FOR TRADE INVESTMENT | YEMEN, DEMOCRATIC | $190.2K | 5 |
| DHL EXEL SUPPLY CHAIN (SWEDEN) AB | SWEDEN | $177.3K | 39 |
| CIPLA COLOMBIA SAS Y/O DEPOSITO UP | COLOMBIA | $128.6K | 8 |
| BREATHEFREE LANKA PRIVATE LIMITED | SRI LANKA | $100.0K | 2 |
| MEDPRO PHARMACEUTICA (PTY) LTD.. | SOUTH AFRICA | $91.3K | 4 |
Cipla Limited supplies Ondansetron to 18 buyers globally. The largest buyer is BREATHEFREE LANKA PVT LTD (SRI LANKA), followed by MEDPRO PHARMACEUTICA (PTY) LTD (SOUTH AFRICA) and CIPLA COLOMBIA SAS Y/O DEPOSITO UPS (COLOMBIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Ondansetron Export Value and How Much Does Cipla Limited Contribute?
India exported $100.2M worth of Ondansetron through 8,469 shipments from 537 suppliers to 157 countries, serving 1,636 buyers globally. Cipla Limited contributes $3.0M to this total, accounting for 2.4% of India's Ondansetron exports. Cipla Limited ships Ondansetron to 8 countries through 18 buyers.
What Is the Average Shipment Value for Cipla Limited's Ondansetron Exports?
Cipla Limited's average Ondansetron shipment value is $14.5K per consignment, based on 204 shipments totaling $3.0M. The largest destination is SOUTH AFRICA (28.5% of Cipla Limited's Ondansetron exports).
How Does Cipla Limited Compare to Other Indian Ondansetron Exporters?
Cipla Limited ranks #10 among 537 Indian Ondansetron exporters with a 2.4% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($31.2M), GLENMARK PHARMACEUTICALS LIMITED ($15.9M), BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED ($10.8M). Cipla Limited processed 204 shipments to 7 destination countries.
What Ondansetron Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| EMESET 4 TABLETS ( ONDANSETRON HYDROCHLO | $269.8K | 10 |
| EMESET INJECTION ( ONDANSETRON HYDROCHLO | $190.2K | 5 |
| ONDANSETRON CIPLA 4MG TABLET (ONDANSETRO | $143.3K | 4 |
| ONCOEMET 8 MG TABLET (ONDANSETRON 8 MG) | $138.7K | 10 |
| ONDANSETRON TABLETS 8 MG ( ONDANSETRON H | $121.9K | 36 |
| EMESET 4 TABLETS (ONDANSETRON HYDROCHLOR | $103.1K | 7 |
| EMESET 4 TABLETS ONDANSETRON HYDROCHLO | $100.0K | 2 |
| ONDANSETRON CIPLA 8MG TABLET (ONDANSETRO | $55.2K | 2 |
| ONDANSETRON CIPLA 4MG TABLET (ONDANSETRON) [10460(PACKS)X1X10'S]NOS | $53.4K | 6 |
| ONDANSETRON CIPLA 8MG TABLET(ONDANSETRON)(1X10X10560 PACK=105600 NOS)NOS | $51.3K | 3 |
Cipla Limited exports 93 distinct Ondansetron formulations including tablets, capsules, syrups, and combination drugs. The top formulation is EMESET 4 TABLETS ( ONDANSETRON HYDROCHLO with 10 shipments worth $269.8K.
Regulatory Requirements: Exporting Ondansetron to Key Markets
What Cipla Limited must comply with to export Ondansetron to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Ondansetron Exporters?
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | GLAND PHARMA LTD | $4.5M | 115 | 2 | $38.9K |
| 9 | ATHENA DRUG DELIVERY SOLUTIONS PRIVATE LIMITED | $3.8M | 102 | 8 | $37.4K |
| 10 | CIPLA LIMITED ★ | $3.0M | 204 | 7 | $14.5K |
| 11 | IPCA LABORATORIES LIMITED | $2.8M | 80 | 3 | $35.4K |
| 12 | INTAS PHARMACEUTICALS LIMITED | $2.5M | 511 | 15 | $4.9K |
Cipla Limited ranks #10 among 537 Indian Ondansetron exporters. Average shipment value of $14.5K compared to the market average of $186.5K. The closest competitors by value are GLAND PHARMA LTD and ATHENA DRUG DELIVERY SOLUTIONS PRIVATE LIMITED.
Which Indian Ports Ship Ondansetron Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 1,058 | 12.5% |
| NHAVA SHEVA SEA (INNSA1) | 1,026 | 12.1% |
| SAHAR AIR | 993 | 11.7% |
| HYDERABAD ICD (INSNF6) | 509 | 6.0% |
| HYDERABAD ICD | 448 | 5.3% |
| JNPT/ NHAVA SHEVA SEA | 343 | 4.1% |
| DELHI AIR CARGO ACC (INDEL4) | 265 | 3.1% |
| AHEMDABAD AIR ACC (INAMD4) | 224 | 2.6% |
Geopolitical & Trade Policy Impact on Cipla Limited's Ondansetron Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Ondansetron, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ondansetron — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ondansetron shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 204 individual customs records matching Cipla Limited exporting Ondansetron, covering 93 formulations to 8 countries via 18 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 157+ countries, 1,636+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ondansetron Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Ondansetron exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Ondansetron Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ondansetron. For current shipment-level data, contact TransData Nexus.